Experimental Typhoid Vaccine 87% Effective In Second Stage Clinical Trial, Study Shows

New York Times: They Swallowed Live Typhoid Bacteria — On Purpose
“…The experimental vaccine was a big success. The trial’s results were published in The Lancet on Thursday: the vaccine turned out to be 87 percent effective…” (McNeil, 9/28).

Reuters: Trial data suggest new typhoid shot could halve infection rate
“A new typhoid vaccine developed by privately held Bharat Biotech proved safe and highly immunogenic in a study and could be used to prevent millions of infections if it succeeds in final-stage clinical trials, researchers said on Friday…” (Kelland, 9/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.